Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 1;28(1):e180-e188.
doi: 10.1097/RHU.0000000000001676.

Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature

Nerea Iniesta Arandia  1 , Gerard Espinosa  1 , Alfredo Guillén Del Castillo  2 , Carles Tolosa-Vilella  3 , Dolores Colunga-Argüelles  4 , Cristina González de Echávarri Pérez de Heredia  5 , Gema M Lledó  1 , Luis Sáez Comet  6 , Norberto Ortego-Centeno  7 , José Antonio Vargas Hito  8 , Manuel Rubio-Rivas  9 , Mayka Freire  10 , Juan José Ríos-Blanco  11 , Mónica Rodríguez-Carballeira  12 , Luis Trapiella-Martínez  13 , Vicent Fonollosa-Pla  2 , Carmen Pilar Simeón-Aznar  2
Affiliations
Review

Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature

Nerea Iniesta Arandia et al. J Clin Rheumatol. .

Abstract

Objectives: To assess the clinical profile of patients with anti-polymyositis/Scl (PM/Scl) antibodies in a cohort of Spanish patients with systemic sclerosis.

Methods: From the Spanish Scleroderma Study Group database, we selected patients in whom PM/Scl antibodies had been tested. We compared demographic, clinical, laboratory, and survival data between patients with and without PM/Scl antibodies.

Results: Seventy-two of 947 patients (7.6%) tested positive for PM/Scl antibodies. Patients with PM/Scl antibodies presented initially with more puffy fingers and arthralgias but less Raynaud phenomenon. Regarding cumulative manifestations, myositis and arthritis were more prevalent in patients with PM/Scl antibodies, as well as pulmonary fibrosis. On the contrary, patients with PM/Scl antibodies had less pulmonary hypertension. No difference in terms of survival at 5 and 10 years was noticed between the 2 groups.

Conclusions: In systemic sclerosis patients from Spain, PM/Scl antibodies are associated with a distinct clinical profile. However, PM/Scl antibodies did not influence survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med . 2009;360:1989–2003.
    1. Denton CP, Khanna D. Seminar systemic sclerosis. Lancet . 2017;6736:1–15.
    1. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am . 2008;34:1–15.
    1. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis . 2007;66:754–763.
    1. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et al. Registry of the Spanish Network for Systemic Sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum . 2012;41:789–800.